Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23321573 | 1.00 | KMT2A (0.35) | KMT2AMEN1CHRM2CHRM5CHRM1 | |
| SCHEMBL16406015 | 1.00 | KMT2A (0.35) | KMT2AMEN1CHRM2CHRM5CHRM1 | |
| SCHEMBL6706088 | 1.00 | KMT2A (0.35) | KMT2AMEN1CHRM2CHRM5CHRM1 | |
| SCHEMBL6361339 | 1.00 | KMT2A (0.35) | KMT2AMEN1CHRM2CHRM5CHRM1 | |
| SCHEMBL2757715 | 1.00 | KMT2A (0.35) | KMT2AMEN1CHRM2CHRM5CHRM1 | |
| SCHEMBL29957418 | 0.85 | CHRM2 (0.36) | KMT2ACHRM2CHRM5CHRM1TSHR | |
| SCHEMBL13114043 | 0.84 | MEN1 (0.35) | KMT2AMEN1CHRM2CHRM5CHRM1 | |
| SCHEMBL10377217 | 0.83 | KMT2A (0.32) | KMT2AMEN1CHRM2CHRM5CHRM1 | |
| SCHEMBL23261025 | 0.82 | CHRM2 (0.34) | CHRM2CHRM5CHRM1TSHRMAPK1 | |
| SCHEMBL23261024 | 0.82 | CHRM2 (0.34) | CHRM2CHRM5CHRM1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957238-B2 | Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-9586911-B2 | Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586911-B2 | Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9102633-B2 | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-5314999-A | Fungicides, amphoteracin derivatives | LABORATOIRES MAYOLY-SPINDLER (FR) | 1994-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | KMT2A 3344/4885MEN1 4638/4885CHRM2 260/4885 |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | KMT2A 3088/4885MEN1 4835/4885CHRM2 173/4885 |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | KMT2A 3088/4885MEN1 4835/4885CHRM2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.